Smith & Nephew SNN posted first-quarter results that were largely consistent with our expectations, and we are standing behind our fair value estimate of $58 per share. As we had suspected, the growth of reconstructive products slowed considerably as Smith & Nephew’s new product cycle is waning just as competitors are launching new products. Nonetheless, the firm plans to launch its new knee system later … Continue reading Smith & Nephew Counters Soft 1Q Reconstructive Sales with Strength in Wound Management